News und Analysen

Since last year, DexCom (NASDAQ: DXCM) has faced a series of issues that have sunk its stock price. The medical device specialist's shares are down 20% over the trailing-12-month period and are

The next three years have just become a bigger question mark for Pfizer (NYSE: PFE) than they were before. There are two competing factors taking shape, one internal to the drugmaker; the other is

As we wind down 2025, the markets are looking shaky and I want my portfolio to be well diversified in the case of a recession or market correction. As such, in today's video I am going to take all

A strong quarter and earnings beat can sometimes give a stock a big boost. But when that doesn't happen, it usually means there are other factors that are weighing on a business and give investors

Until a few weeks ago, I was more than happy to own shares in all three of the major cruise line stocks. Royal Caribbean (NYSE: RCL) was my largest of the three positions, followed by Carnival

UnitedHealth Group (NYSE: UNH) used to be a safe stock to hang on to. Its financials looked impressive, the business got bigger, it boosted its dividend, and it looked like a no-brainer stock to

There's nothing wrong with investing in well-known, market-leading corporations. Many still have excellent prospects and robust underlying businesses. However, it's also worth considering smaller

After the release of the top-line results from its phase 2 clinical trial of its lead drug candidate, VK2735 (oral formulation), in August, there were investors who doubted whether Viking

A $5,000 investment may not seem like a large amount of money to invest in the stock market. But you can make the most of it by investing for the long haul, and picking modestly valued growth

SG Capital Management LLC reduced its holding in Haemonetics Corporation (NYSE:HAE) by 731,892 shares, a position value decline of $59,133,712, per November 07, 2025, SEC filings.

According to a fil

The stock market caters to investors with almost any budget, especially with online brokers offering commission-free trading and fractional shares. Even with a modest sum, you can find quality

Niche healthcare stock Haemonetics (NYSE: HAE) was a winner among the clutch of publicly traded companies reporting quarterly earnings on Thursday. On the back of an estimates-beating second quarter

The "Magnificent Seven" stocks, a group of (mostly) tech giants, are among the most covered companies on Wall Street. The general sentiment about these corporations is that they boast attractive

On Tuesday, Baltimore-based Brown Capital Management reported selling 861,020 shares of Vericel Corporation for an estimated $30.9 million based on the average share price in the third quarter.

The stock market is near all-time highs as Wall Street chugs through earnings season and eyes the end of the year just around the corner.

But not all stocks are hitting new heights. Some prominent

Baltimore-based Brown Capital Management reported a sale of 376,359 Glaukos Corporation shares for an estimated $34.6 million in the third quarter, according to an SEC filing.

Brown Capital

Income investors usually don't mind too much if a stock doesn't deliver tremendous gains, as long as it keeps the dividends flowing. They typically don't like it when a stock tumbles, though, as

Dividend yields are more than just an indication of how much income a stock will generate for investors. High yields are often a sign that a stock is trading hands at an attractive price point. When

On November 5, 2025, Renaissance Group LLC initiated a new position in Halozyme Therapeutics (NASDAQ:HALO), acquiring 478,735 shares for an estimated $35.11 million, according to a recent SEC

One of the healthier stocks in the healthcare field Wednesday was Amgen (NASDAQ: AMGN). The biotech and pharmaceutical company published its third-quarter results the previous day after market

Shares in Viking Therapeutics (NASDAQ: VKTX) rose by a whopping 44.9% in October, according to data provided by S&P Global Market Intelligence. The move occurred in three legs, and each one was

The stock of niche financial software company Vertex (NASDAQ: VERX) didn't get a very good start to the trading week at all. Its value fell by nearly 10% that day, due largely to a quarterly

Bruker (NASDAQ: BRKR) published its latest quarterly earnings report Monday morning, and despite notching a double beat the company's stock took something of a hit. Its price fell nearly 1% by the

On Tuesday, Massachusetts-based Lane Generational disclosed that it sold out of Bruker (NASDAQ:BRKR), liquidating 87,607 shares for an estimated $3.6 million in the third quarter.

According to a

Pharmaceutical maker Eli Lilly (NYSE: LLY) has seen its share price rocket higher by over 500% over the past five years. That stands in stark contrast to a roughly 20% advance for competitor Merck